Company Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.
It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device.
In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community.
Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets.
The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
| Country | United States |
| Founded | 2000 |
| IPO Date | Nov 12, 1986 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 500 |
| CEO | Carrie Eglinton Manner |
Contact Details
Address: 220 East First Street Bethlehem, Pennsylvania 18015 United States | |
| Phone | 610 882 1820 |
| Website | orasure.com |
Stock Details
| Ticker Symbol | OSUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001116463 |
| CUSIP Number | 68554V108 |
| ISIN Number | US68554V1089 |
| Employer ID | 36-4370966 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Carrie Eglinton Manner | President, Chief Executive Officer and Director |
| Kenneth J. McGrath | Chief Financial Officer |
| Michele Anthony | Senior Vice President, Chief Accounting Officer, Controller and Assistant Secretary |
| Karen Davies | Diagnostics Research & Development and Chief Technologist |
| Rafal Iwasiow Ph.D. | Sample Management Solutions Research & Development and Chief Scientist |
| Jason Michael Plagman | Vice President of Investor Relations |
| Stefano Taucer | General Counsel and Corporate Secretary |
| David A. Rappaport C.F.A. | Senior Vice President of Corporate Development, Strategy and Integration |
| Amy Steigerwalt | Senior Vice President of Human Resources |
| Zachary Wert | Senior Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 17, 2026 | SCHEDULE 13D/A | Filing |
| Mar 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 17, 2026 | DFAN14A | Filing |
| Mar 9, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |